Initiation and Engagement of Substance Use Disorder Treatment (IET)

Assesses new episodes of substance use disorder (SUD) in adults and adolescents 13 years of age and older who received:

  • Initiation of SUD Treatment: New episodes, after which the individual initiated treatment through an inpatient SUD admission, outpatient visit, telehealth or intensive outpatient encounter or partial hospitalization, or received medication within 14 days of diagnosis.
  • Engagement of SUD Treatment: New episodes, after which the individual initiated treatment and had two or more additional SUD services or medications within 34 days of the initiation visit.

Why It Matters

In 2022, 48.7 million individuals in the U.S. 12 years of age or older (approximately 17.3% of the population) were classified as having had an SUD within the past year.1 Individuals with SUD are at increased risk of overdose, injury, soft tissue infections and mortality.2 In 2021, drug overdose accounted for 106,699 deaths, representing a 14% increase in overdose deaths compared to 2020.3 Similarly, over 140,000 people die each year from excessive alcohol use.4

Early and regular SUD treatment, including medication therapy, has been demonstrated to improve outcomes for individuals with SUDs.,5–8 but less than 20% of individuals with a SUD receive this important specialty care.9,10

Results – National Results

Initiation of SUD Treatment - Alcohol Abuse or Dependence

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202236.638.142.138.840.8
202136.736.643.137.338.5
202039.138.844.237.839.2
201937.637.542.0§§
201836.637.541.637.939.7
201736.637.44138.642.8

Initiation of SUD Treatment - Opioid Abuse or Dependence

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202242.540.758.333.233.2
202139.738.257.231.330
202040.038.856.331.330.8
201941.239.855.9§§
201840.14152.531.432
20174241.650.231.332.9

Initiation of SUD Treatment - Other Drug Abuse or Dependence

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202235.737.34333.530.7
202134.134.642.731.128.9
202036.936.843.731.528.5
201937.137.843.1§§
201836.63842.33229
201737.138.442.432.632.3

Initiation of SUD Treatment (Total)

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202236.5384535.236.2
202134.134.644.233.132.8
202037.036.645.133.233.7
201936.036.444.0§§
201835.436.242.833.533.9
201736.636.742.333.936.1
201633.533.940.832.736.5
201533.334.538.232.735.2
201434.736.138.332.535.1
201337.640.338.233.737.8
201239.141.239.438.843.3
201140.240.639.24147.6
201042.740.842.944.657.4
200942.74645.646.257.4
200842.442.644.545.949.1
200744.54645.650.356.5
200643.24943.350.350
200544.545.840.750.952.3
200445.945.752.6

Engagement of SUD Treatment - Alcohol Abuse or Dependence

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202212.413.511.54.64.5
202112.313.311.35.15
202012.714.311.04.94.8
201912.413.711.1§§
201811.813.610.94.94.6
201711.813.710.64.64.3

Engagement of SUD Treatment - Opioid Abuse or Dependence

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202221.620.330.37.56.4
202118.918.528.48.15.2
202019.219.427.87.45.8
201919.520.028.1§§
201819.520.325.65.33.9
201720.121.222.24.83.8

Engagement of SUD Treatment - Other Drug Abuse or Dependence

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202212.213.612.33.93.1
202110.712.311.23.53
202011.713.811.23.72.8
201911.814.311.6§§
20181213.911.73.72.6
201712.314.111.63.82.9

Engagement of SUD Treatment (Total)

Measure YearCommercial HMOCommercial PPOMedicaid HMOMedicare HMOMedicare PPO
202213.114.214.954.6
202111.71313.95.24.5
202012.614.014.15.14.5
201912.413.914.4§§
201812.213.8144.53.9
201712.514.313.54.43.6
201611.312.912.53.63.4
201511.813.510.23.22.9
201412.814.211.33.33.5
201313.714.810.63.23.5
201213.614.610.83.13
201115.21611.93.73.8
201015.61614.23.73.8
200916.115.712.34.64.2
200816.216.212.44.39.4
200715.215.214.44.56.3
200613.81611.74.57
200514.115.39.74.73.2
200415.5_11.97.1_

§ Not available due to CMS suspension of data reporting during COVID-19 pandemic.

This State of Healthcare Quality Report classifies health plans differently than NCQA’s Quality Compass. HMO corresponds to All LOBs (excluding PPO and EPO) within Quality Compass. PPO corresponds to PPO and EPO within Quality Compass.

Figures do not account for changes in the underlying measure that could break trending. Contact Information Products via my.ncqa.org for analysis that accounts for trend breaks.

References

  1. Substance Abuse and Mental Health Services Administration. 2023. “Key Substance Use and mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health.” HHS Publication No. PEP23-07-01-006, NSDUH Series H-58. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-nsduh-nnr.pdf
  2. Bahorik, A.L., D.D. Satre, A.H. Kline-Simon, C.M. Weisner, C.L. Campbell. 2017. “Alcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System.” J Addiction Medicine 11(1),3–9.
  3. Centers for Disease Control and Prevention. 2023. “Drug Overdose Deaths.” https://www.cdc.gov/drugoverdose/deaths/index.html
  4. Centers for Disease Control and Prevention. 2022. “Deaths from Excessive Alcohol Use.” https://www.cdc.gov/alcohol/features/excessive-alcohol-deaths.html#:~:text=More%20than%20140%2C000%20people%20die,in%20the%20U.S.%20each%20year.
  5. Kampman, K., K. Freedman. 2020. “American Society of Addiction Medicine (ASAM) National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.” Journal of Addiction Medicine 14, no. 2S: 1–91, https://doi.org/10.1097/ADM.0000000000000633.
  6. Reus, V. et al. 2018. “Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder.” American Journal of Psychiatry 175(1), 86–90. doi:10.1176/appi.ajp.2017.1750101
  7. Department of Veteran Affairs, Department of Defense. 2015. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington DC: Department of Veterans Affairs, Department of Defense.
  8. Michigan Quality Improvement Consortium. August 2015. “Screening, Diagnosis and Referral for Substance Use Disorders.” Southfield (MI): Michigan Quality Improvement Consortium. 1 p.
  9. Substance Abuse and Mental Health Services Administration (SAMHSA). 2019. “Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use
  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.